stemcell
The Niche

The Niche

Knoepfler lab stem cell blog

  • Home
  • Contact
  • About Us
  • Trial search
  • Treatments
  • Report a clinic
  • RMAT List (37)
  • TED talk
  • Nature
  • Privacy
  • Stem Cell Book
  • Dragon book
  • 2019 Meetings
  • 2020 Meetings
  • Stem cells in your language

Paul Laikind

ViaCyte CyT49 PSC

ViaCyte Q&A: CRISPR Tx quick progress, ongoing diabetes trial, & more

September 25, 2019 Paul Knoepfler 8

ViaCyte is one of the most exciting stem cell and regenerative medicine biotech companies so I like to try to check in with them regularly. Today’s post is my new interview with ViaCyte leader Paul Laikind on recent developments. We […]

VC-01 post-implant final

Quick Q&A with ViaCyte CEO on CRISPR-stem cell work

September 19, 2018 Paul Knoepfler 4

We heard this week about the encouraging news of a new CRISPR-stem cell collaboration between stem cell biotech ViaCyte and CRISPR Therapeutics. The goal of the team is to make genetically engineered pancreatic derivatives from stem cells that would have […]

ViaCyte

ViaCyte & CRISPR Therapeutics team up to battle diabetes

September 17, 2018 Paul Knoepfler 2

What happens when one of the most exciting stem cell biotechs ViaCyte teams up with a firm like CRISPR Therapeutics to use a combination of gene editing and cell therapy? Hopefully a synergistic partnership emerges that in this case can […]

ViaCyte

ViaCyte Interview on Diabetes Stem Cell Trials & Cool Role of Gore-Tex Tech

October 18, 2017 Paul Knoepfler 2

When I think of the promise of stem cells for diabetes, the privately held California stem cell firm ViaCyte is the first biotech that comes to mind now. It has promising stem cell clinical trial work building. Today’s post is […]

VC-01 post-implant final

Stem cell therapy review of good news: UC Davis, Asterias, Cynata, Mesoblast, ViaCyte

August 27, 2017 Paul Knoepfler 1

It’s a difficult, but very important road to conclusively prove that an investigational stem cell therapy is both safe and effective in order to get final approval FDA or equivalents in other countries. For this reason, it is beneficial to […]

Posts navigation

1 2 »

Subscribe to this Blog

Join 24,206 other subscribers

Paul KnoepflerFollow

Prof @UCDAVIS Stem cells & Kids Brain Cancer Epigenomics #CRISPR Science policy/ethics. #scicomm TED https://t.co/4XhF0V5XiZ New book on making dragons🐲https://t.co/q9ezUzZdtx

Paul Knoepfler
pknoepflerPaul Knoepfler@pknoepfler·
8h

From @Naure 'Rogue stem-cell salesman Davide Vannoni dies' at 53 https://www.nature.com/articles/d41586-019-03823-7 "He was not a trained scientist or physician... But in 2007 he claimed to have invented a stem-cell therapy that could cure" via phony Stamina Foundation. #stemcells

Reply on Twitter 1206426394189680640Retweet on Twitter 12064263941896806404Like on Twitter 12064263941896806404Twitter 1206426394189680640
pknoepflerPaul Knoepfler@pknoepfler·
11h

ICYMI: Top post of December so far on The Niche: New pub on monkey-pig chimeras is mostly discouraging for similar human research toward organ transplants https://ipscell.com/2019/12/monkey-pig-chimeras-pub-discouraging-for-similar-human-research-toward-organ-transplants/ #stemcells #biology

Reply on Twitter 1206391009371779072Retweet on Twitter 12063910093717790723Like on Twitter 12063910093717790725Twitter 1206391009371779072
pknoepflerPaul Knoepfler@pknoepfler·
16h

Vermont has a problem with unproven stem cell clinics. The state has a plan of action including possible legislation https://ipscell.com/2019/12/vermont-zeroes-in-on-unproven-stem-cell-clinics/ #stemcells #stemcell

Reply on Twitter 1206313245251784704Retweet on Twitter 12063132452517847047Like on Twitter 12063132452517847045Twitter 1206313245251784704
Load More...
  • RSS - Posts
  • RSS - Comments

Recent Comments

  • Gerard Malanga on Vermont zeroes in on unproven stem cell clinics
  • Bill Jones on FDA spike: clinic supplier Liveyon warning letter & 483s; notice on exosome harms
  • Sudjar on Northwestern abruptly ending Burt HSCT autoimmune trials
  • Paul Knoepfler on FDA spike: clinic supplier Liveyon warning letter & 483s; notice on exosome harms
  • Bill Jones on FDA spike: clinic supplier Liveyon warning letter & 483s; notice on exosome harms

Copyright © 2019 | Knoepfler Lab Stem Cell Blog, UC Davis, 1 Shields Ave, Davis, CA 95616. Designwork by Tradesouthwest Top